Bernard (Beej) Macatangay, MD, has been appointed as the new Chief, Division of Infectious Diseases in the Department of Medicine, effective April 16, 2024. Dr. Macatangay is an Associate Professor of Medicine and Immunology at the University of Pittsburgh School of Medicine. He graduated from the University of the Philippines College of Medicine and worked on parasitology research at the University of the Philippines College of Public Health before doing his Internal Medicine residency at the Boston University Program at Roger Williams Medical Center. He completed his General Infectious Diseases and his HIV/AIDS Clinical and Research fellowships at the University of Pittsburgh and served as Chief Fellow.
Dr. Macatangay is a highly innovative physician-scientist whose translational and clinical research focuses on the role of immune regulatory mechanisms and pathways in chronic HIV-associated inflammation and evaluating immunotherapeutic strategies to achieve HIV remission off antiretroviral therapy. As the Associate Director and later Co-Director of the University of Pittsburgh Immunology Specialty Laboratory (ISL), one of three ISLs in the country, Dr. Macatangay provides HIV immunology expertise and led the investigation of the immunologic sections of several national and international clinical trials in the ACTG (Advancing Clinical Therapeutics Globally for HIV and other Infections), an NIH-funded global clinical trials network. As the Clinical Laboratory Director of the Pitt Clinical Research Site, his laboratory provides specimen processing services for HIV clinical trials, and these services significantly expanded during the start of COVID19 pandemic to support multiple ongoing COVID-19 studies including the early vaccine studies. As Director of Student and Resident ID Research and the Research Associate Program Director for the ID Fellowship Training Program, he has been instrumental in starting the Infectious Diseases AOC in the School of Medicine, facilitating ID scholarly projects for students, residents, and fellows, and recruiting of ID physician-scientist trainees to the ABIM Research Pathway.
Please join us in congratulating Dr. Macatangay on his new appointment.